Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.36 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496919 | 0.89 | MAPT (0.53) | NR1H2NR1H3ALDH1A1MCL1LMNA | |
| SCHEMBL6485470 | 0.82 | ALDH1A1 (0.42) | NR1H2NR1H3ALDH1A1MCL1HSD17B10 | |
| SCHEMBL6484817 | 0.80 | SMARCA2 (0.52) | NR1H2ALDH1A1MAP4K4LMNANPSR1 | |
| SCHEMBL23216745 | 0.75 | NR1H2 (0.42) | NR1H2NR1H3ALDH1A1MCL1HSD17B10 | |
| SCHEMBL29886232 | 0.75 | NR1H2 (0.42) | NR1H2NR1H3ALDH1A1MCL1HSD17B10 | |
| SCHEMBL29768486 | 0.75 | NR1H2 (0.42) | NR1H2NR1H3ALDH1A1MCL1HSD17B10 | |
| SCHEMBL25134616 | 0.75 | AGTR2 (0.57) | NR1H2NR1H3ALDH1A1LMNA | |
| SCHEMBL20874055 | 0.74 | MAP4K4 (0.51) | NR1H2NR1H3ALDH1A1HDAC1MAP4K4 | |
| SCHEMBL20884865 | 0.74 | MAP4K4 (0.51) | NR1H2NR1H3ALDH1A1HDAC1MAP4K4 | |
| SCHEMBL20884630 | 0.74 | MAP4K4 (0.51) | NR1H2NR1H3ALDH1A1HDAC1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | NR1H2 674/4885NR1H3 1048/4885ALDH1A1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.